| Crystal Marie Deguzis, MS CCC-SLP | |
|
105 Eastern Ave, Rochester, NH 03867-2007 | |
| (603) 332-2848 | |
| Not Available |
| Full Name | Crystal Marie Deguzis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 105 Eastern Ave, Rochester, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215310057 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP2415 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Crystal Marie Deguzis, MS CCC-SLP 105 Eastern Ave, Rochester, NH 03867-2007 Ph: (603) 332-2848 | Crystal Marie Deguzis, MS CCC-SLP 105 Eastern Ave, Rochester, NH 03867-2007 Ph: (603) 332-2848 |
News Archive
Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.
YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist - PAS-YNSα8 - which has been jointly developed by scientists at the Weizmann Institute and XL-protein.
A new patent has been issued to Moffitt Cancer Center for a computerized system that efficiently selects the right patient for the right clinical trial. The newly patented system matches the registered patient's own molecular profile - warehoused in a database of thousands of patient-donated biological tissue or tumor samples - to the molecular design of the drug aimed at targeting their disease at the molecular level, and does it quickly.
The study began by taking the medical history of 11 children, all of whom had a disorder due to mycobacteria infections, as the basis. All were discovered to have the same phenotype with the same mutation, which was located in the interferon-gamma (IFNGR) receptor, so the group began to explore what was causing this dysfunction.
› Verified 8 days ago
Devin Connors, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 59 Brock St, Rochester, NH 03867 Phone: 603-332-2180 | |
Shara Hughes, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10 Railroad Ave, Rochester, NH 03839 Phone: 603-332-6487 | |
Jessica Tatum Regan, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 130 Wakefield St, Rochester, NH 03867 Phone: 508-826-3939 | |
Kristen G Hughes, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12 Hale St, Rochester, NH 03867 Phone: 603-312-5513 | |
Mrs. Emily Tilton Creteau, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 19 Walnut St, Rochester, NH 03867 Phone: 207-752-1153 | |
Martina Harrington, M.A. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 130 Wakefield St, Rochester, NH 03867 Phone: 603-332-0757 |